1. Class 1 new drug Viagra obtained clinical approval; Jilin Yatai increased capital to acquire Weikeli

On April 11, Jilin Yatai (Group) Co., Ltd announced that Jiangsu Weikeli Pharmaceutical Technology Co., Ltd had obtained the approval document for clinical trials of drugs In 2015, the third interim Board of directors of the company deliberated and passed the proposal on the acquisition and capital increase of Jiangsu Weikeli Pharmaceutical Technology Co., Ltd (hereinafter referred to as "Weikeli technology"), and Jilin Yatai Group Pharmaceutical Investment Co., Ltd., a wholly-owned subsidiary of the company, contributed 15 yuan, After the acquisition and capital increase of part of the equity of Weikeli technology by RMB 10 million, Jilin Yatai Group Pharmaceutical Investment Co., Ltd will hold 60.09% of the equity of Weikeli technology On the morning of March 20, Jilin Yatai group (listed on the Shanghai Stock Exchange and China's top 500) pharmaceutical investment Co., Ltd signed an equity purchase and sale agreement with Jiangsu Weikeli Pharmaceutical Technology Co., Ltd in Changchun Professor Sun Hongbin, honorary chairman of Jiangsu Weikai company, Qu Jun, chairman of the board, Yuan Fang, general manager, and CAI Hongyou, shareholder, attended the signing ceremony According to the agreement, Yatai pharmaceutical investment Co., Ltd purchased 60.09% of Jiangsu Weikeli company for 150 million yuan At the signing ceremony, song Shanglong, chairman and President of Yatai group, attended the meeting and said that this acquisition is the third acquisition project after the group company determined the pharmaceutical industry as the pillar industry, and also an important project for the large-scale and intensive development of the pharmaceutical industry According to the overall development strategy and market demand, increase R & D investment, strive to further improve the R & D ability and innovation ability of Jiangsu Weikeli, and accelerate the development of a batch of fist products with independent intellectual property rights and advanced level at home and abroad
Recently, wilkar technology has received the notice of approval opinions and approval documents for clinical trials of new chemical drug 1.1, Viagra API (approval No.: 2015l00565), Viagra tablet (2.5mg) and Viagra tablet (approval No.: 2015l00539) issued by the State Food and drug administration g) The approval document for clinical trials of drugs (approval document No.: 2015l00540) and the approval document for clinical trials of Viagra tablets (25mg) (approval document No.: 2015l00541) agree to conduct clinical trials Vecargrel is a kind of new chemical medicine, which can inhibit platelet aggregation after two steps of metabolism activation in human body It is a kind of platelet aggregation inhibitor for patients with acute coronary syndrome The project has applied for 9 domestic patents and 4 international patents The international patents of the project have been disclosed to 6 countries and regions in the United States, the European Union, Japan, South Korea, India and Canada On July 8, 2014, the project was granted the U.S patent (Patent No.: us8772489) The R & D project has been successively supported by 7 science and technology funds of governments at all levels, including the Ministry of science and technology, Jiangsu Province and Nanjing city.